Unsafe
Not Aligned
Patient Risk:
Moderate
Summary
Most mechanism/clinical-expectation claims (e.g., coenzyme Q10 interference, membrane disruption, mitochondrial effects, satellite cell/myoblast mechanisms, delayed recovery after training, and exercise modality triggers) are not supported by the provided Lipitor label excerpts. Only general musculoskeletal risk concepts (myopathy/rhabdomyolysis, muscle pain/weakness/tenderness) and some interaction risk statements (cytosporine; fibric acid derivatives; erythromycin; clarithromycin; strong CYP3A4 inhibitors generally) appear consistent with the provided text.
Category Scores
Accurate Statements
Statins can cause muscle pain.
5.1 Skeletal Muscle: myopathy defined as muscle aches or muscle weakness; patients should report unexplained muscle pain, tenderness, or weakness. 17.1 Muscle Pain: risk of myopathy and report promptly unexplained muscle pain, tenderness, or weakness.
Statins can cause muscle weakness.
5.1 Skeletal Muscle: myopathy defined as muscle aches or muscle weakness; report promptly unexplained muscle pain, tenderness, or weakness.
Statins can cause rhabdomyolysis in rare cases.
5.1 Skeletal Muscle: Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class.
Cyclosporine increases the risk of statin-related muscle side effects.
5.1 Skeletal Muscle: concomitant use with cyclosporine increases the risk of myopathy/rhabdomyolysis; risk increased with concurrent administration of cyclosporine. 7.3 Cyclosporine: bioavailability increases; 7 overall also lists cyclosporine as increasing myopathy risk.
Gemfibrozil increases the risk of statin-related muscle side effects.
5.1 Skeletal Muscle: risk increased with concurrent administration of fibric acid derivatives.
Erythromycin increases the risk of statin-related muscle side effects.
5.1 Skeletal Muscle: risk of myopathy increased with concurrent administration of erythromycin.
Hypothyroidism raises the risk of statin-related muscle side effects.
Unsupported by provided excerpt: label text provided does not mention hypothyroidism as a risk factor.
Age raises the risk of statin-related muscle side effects.
8.5 Geriatric Use: advanced age (≥65) is a predisposing factor for myopathy; caution.
Unsupported Statements
Statins are used to lower cholesterol.
Provided excerpts are from section 12.1 mechanism, which describes cholesterol lowering, but no explicit indication/usage statement is present in the supplied label text.
The effects of statins on muscle are associated with interference with coenzyme Q10 production.
Not supported by provided label excerpts (mechanism or skeletal muscle section provided does not mention coenzyme Q10).
Statins disrupt muscle cell membranes.
Not supported by provided label excerpts.
Statins impair mitochondrial function in muscle cells.
Not supported by provided label excerpts.
Statin-related mechanisms can prolong recovery between workouts or after injury.
Not supported by provided label excerpts (no recovery-after-exercise/joint-injury claims).
Research shows statins can slow muscle regeneration after damage.
Not supported by provided label excerpts; no mention of muscle regeneration.
Statins interfere with satellite cell activation.
Not supported by provided label excerpts.
Statins interfere with myoblast fusion.
Not supported by provided label excerpts.
Interference with satellite cell activation and myoblast fusion can slow muscle rebuilding.
Not supported by provided label excerpts.
Some patients report needing more days between training sessions when taking statins.
Not supported by provided label excerpts.
Patients taking Lipitor and other statins report delayed-onset muscle soreness lasting longer than the usual 24–48-hour window.
Not supported by provided label excerpts; label only advises reporting unexplained muscle pain/tenderness/weakness and discusses risk factors/monitoring, not specific timing windows.
Patients taking Lipitor and other statins report muscle tenderness.
The label does mention muscle tenderness as a symptom to report, but the claim is partially unsupported because it is framed as a general patient-reported outcome; however the symptom presence is supported. (Flagged as unsupported for prevalence/reporting language not present in label.)
Patients taking Lipitor and other statins report muscle stiffness.
Not supported by provided label excerpts (symptoms listed: muscle pain, tenderness, weakness; no 'stiffness').
Patients taking Lipitor and other statins report muscle fatigue.
Not supported by provided label excerpts.
Patients describe muscle tenderness, stiffness, and fatigue that extends beyond the normal 24–48-hour window.
Not supported by provided label excerpts (no stiffness/fatigue; no 24–48-hour window).
Many patients stop or switch statins after experiencing persistent muscle soreness.
Not supported by provided label excerpts (no statements about patient behaviors or frequency).
High-intensity training while on Lipitor increases the risk of muscle symptoms.
Not supported by provided label excerpts.
Eccentric exercises increase the risk of statin-associated muscle symptoms.
Not supported by provided label excerpts.
Eccentric moves such as downhill running can trigger statin-associated muscle symptoms more than concentric exercises.
Not supported by provided label excerpts.
Heavy lowering phases of lifts can trigger statin-associated muscle symptoms more than concentric exercises.
Not supported by provided label excerpts.
Hydrophilic statins such as pravastatin are less likely to penetrate muscle cells.
Not supported by provided label excerpts (no discussion of hydrophilic vs lipophilic statins or muscle penetration).
Some patients seek advice on using dose reduction or hydrophilic statins such as pravastatin to reduce risk of muscle symptoms.
Not supported by provided label excerpts.
The statement "Companies seek generic entry before 2028 for several statin formulations" asserts an intended generic entry timeline for statins.
Not supported by provided label excerpts; the provided content does not include generic-entry timelines.
Contradictions
Important Omissions
Whether 'muscle weakness' or 'muscle tenderness' were linked to CK/CPK elevations (>10× ULN) and the need to discontinue therapy with markedly elevated CPK or diagnosed/suspected myopathy.
Importance:
Moderate
Label-based advice on reporting unexplained muscle pain/tenderness/weakness and that risk is increased with certain drug classes (e.g., fibric acid derivatives, niacin, azole antifungals, strong CYP3A4 inhibitors) and with grapefruit juice (>1 liter) in counseling info.
Importance:
Moderate
Specific interaction prescribing recommendations for cyclosporine (do not exceed 10 mg atorvastatin daily) and caution dosing thresholds for clarithromycin/HIV protease inhibitors/itraconazole (caution when exceeding 20 mg), since the claims only broadly state increased risk without label dosing limits.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported mechanistic explanations and unlabelled exercise-timing triggers could mislead interpretation of when muscle symptoms occur or how risk is driven, even though some symptom language and known drug-interaction risk factors (e.g., cyclosporine, erythromycin; fibric acid derivatives; advanced age) are consistent with provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are mechanistic or lifestyle/exercise timing statements that are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported elements from the provided sections: skeletal muscle adverse effects (myopathy symptoms; rare rhabdomyolysis with AKI/myoglobinuria), label-listed risk factors and interacting drugs (cytosporine; fibric acid derivatives; erythromycin; clarithromycin/itraconazole/HIV protease inhibitors as strong CYP3A4 inhibitors) and label-described monitoring/withholding/discontinuation guidance. Remove or qualify mechanistic and exercise-specific timing claims and the generic-entry timeline claim unless supported by label text.